In this article in The American, a journal of the American Enterprise Institute for Public Policy Research, Roger Bate, the Legatum Fellow at the American Enterprise Institute, and Richard Tren, director of Africa Fighting Malaria, write that the Global Fund to Fight AIDS, Tuberculosis, and Malaria “launched a $225 million facility that offers subsidized malaria drugs …provid[ing] subsidies so that shops can sell relatively expensive drugs at low cost, thereby using the reach and power of markets to save lives,” they write, adding that the mechanism “is perverting the market for malaria drugs and could do more harm than good.” The authors call on Congress to examine the subsidy system, writing, “The United States is not funding the subsidy, but the subsidy is harming programs the United States is supporting. Understanding and then stopping wasteful spending decisions would save money and lives” (9/8).
“Burundian NGOs say at least 20 people have died” as a result of a “months-long shortage” of antiretroviral drugs (ARVs), although “Ministry of Health officials could not be reached to confirm the number of people affected,” PlusNews reports. “More than 60,000 Burundians need HIV treatment, but only about 25,000 have access to ARVs,” according to the news agency, which adds, “The shortage has been blamed on dwindling donor funds and a disorganized health ministry.”
ABC Radio Australia’s “Connect Asia” features an interview with Christophe Benn, director of external relations for the Global Fund to Fight HIV, Tuberculosis and Malaria. Benn said “it has become much more difficult to mobilize resources” since the 2008-09 economic downturn and “a great deal of mobilization, both of public and private donors” is needed to maintain ongoing projects that receive donations from the Global Fund (Cochrane, 8/23).
Natasha Bilimoria, president of Friends of the Global Fight Against AIDS, Tuberculosis and Malaria, discusses the importance of faith-based organizations in battling malaria in this post on the Bill & Melinda Gates Foundation’s “Impatient Optimists” blog. “Reaching people where they live, work and worship is as important for supporters as…
The Global Fund to Fight AIDS, Tuberculosis and Malaria, which “froze disbursements of its AIDS grant to China in November and all other grants in May over suspected misuse of the money and the government’s reluctance to involve community groups, … said Tuesday that it was lifting the freeze on financing to ensure that AIDS work in China continued while it worked with government officials, representatives from United Nations agencies and private groups to resolve the dispute,” the Associated Press reports.
In a Malaria Policy Center “Malaria Watch TV” video post, U.S. Global Malaria Coordinator Rear Admiral Tim Ziemer “speak[s] with the Malaria Policy Center about the status of the malaria fight and how the U.S. is leading the way against this preventable and treatable disease,” the organization writes. The “U.S.…
With the new knowledge that providing antiretroviral (ARV) treatment to people living with HIV “contribut[es] to a sharp slowdown in the spread of the virus,” “scaling up treatment now may prove to be the least expensive option if we want to bring this deadly pandemic, which still infects 1.8 million people every year, under control,” Michel Kazatchkine, executive director of the Global Fund to Fight AIDS, Tuberculosis and Malaria writes in the Guardian’s “Poverty Matters Blog.”
Several donors to the Global Fund to Fight AIDS, Tuberculosis and Malaria “continue to hold back their contributions for this year â€¦ add[ing] up to more than $500 million that the Global Fund had been counting on for this year out of a total budget of about $3 billion,” the Lancet reports.
“Reducing commodity costs [for antiretroviral drugs] by a mere five to 10 percent can represent hundreds of millions of dollars in savings for the global community. In turn these savings translate into millions of more patients who can receive access to life-saving treatment,” David de Ferranti, president of Results for Development Institute (R4D), and Kanika Bahl, managing director at R4D, write in a Huffington Post opinion piece. They discuss a strategic plan for increasing access to and lowering the cost of antiretroviral drugs (ARVs) that R4D developed for the Global Fund to Fight AIDS, Tuberculosis and Malaria.
“The neglected tropical diseases (NTDs) produce a devastating level of chronic disability in sub-Saharan Africa, with some estimates suggesting that the NTD disease burden exceeds tuberculosis and is one-half that of malaria,” Julie Noblick and Richard Skolnick of George Washington University and Peter Hotez of the Sabin Vaccine Institute write in a PLoS Neglected Tropical Diseases editorial. With noted relationships between the prevalence of NTDs and HIV, the diseases “demand a public health response from the established global HIV/AIDS community, in parallel with efforts to scale up NTD control,” they argue.